The first diagnostic test to classify cancers by differences in microRNAs–small pieces of RNA that regulate genes–will soon be on the market. The test distinguishes two types of lung cancer and should help doctors tailor treatments to their patients’ needs. Scientists say that tests based on microRNA profiles could prove more sensitive and reliable than existing methods, whose accuracy depends heavily on the judgment of the people analyzing them.
Product: MicroRNA test for lung cancer
Cost: Comparable to that of other molecular tests for cancer, which are priced at around $3,000 to $3,500
Company: Rosetta Genomics
Other products in this section:
Become an Insider to get the story behind the story — and before anyone else.
Subscribe to Continue Reading
Uh oh–you've read all of your free articles for this month.
How to Spend $1,900 on Gene Tests Without Learning a Thing
Science and marketing clash in the “jungle” of direct-to-consumer DNA apps.
FDA Vote Sets Stage for Gene Therapy’s Future
The pioneering treatment fixes a mutated gene and could soon be available in the U.S.
Inside the Moonshot Effort to Finally Figure Out the Brain
AI is only loosely modeled on the brain. So what if you wanted to do it right? You’d need to do what has been impossible until now: map what actually happens in neurons and nerve fibers.